Motorola Inc. (NYSE:MOT) announced that Motorola together with its subsidiary, Symbol Technologies, Inc. and Janam have reached an agreement that settles all outstanding intellectual property disputes between the two companies. In 2008, Symbol Technologies, Inc. filed a patent infringement lawsuit against Janam for infringement of patents related to mobile computing technologies.
The agreement today ends all pending litigation. Under the settlement agreement, Janam has taken a royalty-bearing license under Symbol's patents in the fields of mobile computing, wireless technology and laser- and imaging-based barcode scanning for finished mobile computing terminals.
Motorola, Inc. offers technologies, products, and services for mobile communications worldwide. It operates in three segments: Mobile Devices, Home and Networks Mobility, and Enterprise Mobility Solutions.
POWER 3 MEDICAL PRODUCTS (OTC BB: PWRM.OB)
Power3 Medical works with key physician scientists at major medical research and treatment centers.
Power3 Medical Products, Inc ., a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, announced recently that it delivered four poster presentations at the 2010 International Conference on Alzheimer's Disease (ICAD ) in Honolulu, Hawaii.
These presentations discussed NuroPro®, Power3's diagnostic test, and focused on Power3's Alzheimer's disease blood serum biomarkers, test and clinical validation trials.
PWRM has the cutting edge technology to find Alzheimer's disease, Parkinson's Disease, and certain types of cancers.
Alzheimer's has no current cure, nonetheless treatments designed for conditions can be purchased and research continues on.
Even though most current Alzheimer treatments can't eliminate Alzheimer's disease from progressing, they're able to temporarily impede the worsening connected with symptoms as well as advance well being for anyone with Alzheimer's not to mention all their caregivers.
With access to decisive human clinical samples and superior trade secret proteomic methodologies, the Company provides solutions to pressing challenges in diagnosis and treatment of patients and has concluded research agreements, technology license agreements, and filed provisional and utility patents.
Power3 is also adding additional layers of research and license agreements, patent filings, and trade secrets, as its technology and product portfolio develops.
Parkinson's disease (PD) is associated with a group of disorders called motor system disorders, which are the result of the losing of dopamine-producing brain cells. Some symptoms of PD are generally tremor, or moving in hands, arms, legs, jaw, and face; hardness, or maybe tightness of the limbs and trunk or reduced balance as well as co-ordination.
Since these symptoms become evident slowly, patients eventually may have challenges in walking, talking, or performing many very simple tasks.
Power3 has filed several patent applications for its NuroPro ® technology that are currently pending.
Power3 also has a world-wide exclusive license from the Baylor College of Medicine in Houston, Texas.
Power3 continues its quest to find a cute to these diseases or diagnose them sooner to be treated before major symptoms become apparent.
To learn more about PWRM please visit: http://www.Power3Medical.com.
DCT Industrial Trust Inc. (NYSE:DCT) a leading industrial real estate company, announced it has completed three acquisitions totaling 332,900 square feet for $20.2 million located in the Seattle, Chicago and Houston markets.
In Seattle, DCT Industrial acquired a 196,525 square foot bulk distribution building located in the Sumner submarket for $13.2 million.
The building, constructed in 2006, is state-of-the-art with 30-foot clear height and ESFR sprinklers and is fully leased through 2020. The purchase price was $67.42 per square foot, or approximately 10% below replacement cost and is expected to generate a year-one, cash yield of 7.1%. This acquisition brings DCT Industrial's Seattle portfolio to 1.3 million square feet and 97% occupied.
DCT Industrial Trust Inc. operates as a publicly owned real estate investment trust. The firm provides its services to companies. Through its fund, it engages in the ownership, operation, and development of real estate properties.
Orofino Gold Corp. (ORFG.PK) is a China based gold producer with one producing gold mine in Colombia and an option on a strong portfolio of small producers and development/exploration assets in Colombia.
Orofino Gold was founded as a private company in 2009 by former executives and management with over 50 years of combined mining exploration, finance and development experience.
Orofino’s corporate objective is to continue to build shareholder value through the exploration and development of existing projects and additional accretive acquisitions, capitalizing on the extensive experience and relationships that management has developed over the past 25 years.
Orofino has acquired a database comprised of exploration and mining results from previous operators who left when the global mining sector experienced a major downturn in the 1997-2000 time frame.
The second part of the Company’s strategy to become a recognized player in the Colombia mining sector was the acquisition of an interest in an operating mine. The Company has acquired a 55% interest in the La Azul/La Estrella property with the rights to acquire up to 80%.
Boston Scientific Corporation (NYSE:BSX) announced that they welcomed the publication of an analysis from its ALTITUDE® Clinical Science program in the current issue of Circulation that showed patients followed by the LATITUDE® Patient Management system experienced a 50 percent relative reduction in the risk of death compared to patients followed in-clinic only.
The analysis also showed that heart failure patients who transmitted weight and blood pressure data via the LATITUDE system experienced an additional 10 percent reduction in the risk of death compared to other CRT-D patients followed by the LATITUDE system. Boston Scientific has enrolled more than 180,000 patients on the LATITUDE system since its introduction in 2006.
Boston Scientific Corporation develops, manufactures, and markets medical devices used in various interventional medical specialties worldwide. It offers cardiac rhythm management products, which monitor the heart and deliver electricity to treat cardiac abnormalities.
Sign-Up For Free Stock Alerts At http://crwepicks.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.The CRWEPicks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer ( http://crwepicks.com/disclaimer ) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEPicks.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. ( read more ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.
Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (OTC:PWRM).
Crown Equity Holdings Inc. (OTCPK:CRWE) has received 500,000 shares of 144 stock in Orofino Gold Corp. (PINK SHEETS: ORFG) valued at sixty five thousand dollars, and 500,000 shares of free trading shares valued at sixty five thousand dollars from a third party (QU CUI You) for 30 days advertising.